Which Third-Party API Suppliers Sell to Generic Drug Companies?
TL;DR
We explain which third-party API suppliers can serve generic-drug buyers by separating merchant catalogs, captive production, and custom CDMO work. We show how to verify actual external availability with product-level regulatory, site, commercial-status, and supply-chain evidence, then choose catalog sourcing, custom development, or dual qualification.
Generic medicines account for more than 90% of prescriptions filled in the United States, making API sourcing a core commercial and quality decision for finished-dose manufacturers. FDA data
Third-party API suppliers serve generic drug companies in three ways: merchant manufacturers sell established APIs externally, integrated drug companies release selected molecules beyond captive use, and CDMOs make customer-specific compounds. The useful comparison is not the largest corporate portfolio. It is a current, externally purchasable API from a named site, with credible dossier, capacity, and supply evidence.
We built this market map to help buyers distinguish an apparent API portfolio from a source that can actually support a generic program.
Which Third-Party API Suppliers Sell to Generic Drug Companies?
The first split is operating model. A supplier may manufacture APIs at scale yet reserve most output for internal finished-dose products, while another may make its business by selling APIs to external customers. Neither model is automatically better, but they demand different evidence.
| Supplier Class | Captive Supply | Third-Party Catalog | Custom Manufacturing | Therapeutic Breadth | Regulatory Evidence | Last Verification |
|---|---|---|---|---|---|---|
| Aarise Pharma | Confirm by molecule and site | We list B2B APIs and pharmaceutical raw materials for international buyers | Finished-dose contract work is publicly described | Steroids, peptides, hormones, and general pharmaceutical APIs require molecule-level confirmation | CoA and MSDS are stated, DMF and CEP support require exact-product confirmation | September 16, 2026 |
| Merchant API Manufacturer Cohort | Usually limited | Core business model is external API supply | Varies by supplier | Often broad in selected chemistry platforms | Dossier and site evidence must match the offered API | September 16, 2026 |
| Integrated Manufacturer Cohort | Usually substantial | Selected molecules may be offered externally | Varies by supplier | Corporate therapeutic reach can exceed external availability | External status cannot be inferred from internal production | September 16, 2026 |
| Custom CDMO Cohort | Customer-directed | Usually not a standing commercial catalog | Core business model | Defined by customer projects and technology platform | Evidence is project, site, and contract specific | September 16, 2026 |
What Counts as External Availability?
We treat an API as externally available only when a buyer can identify a legal seller, pursue a current quote or inquiry, and verify the material’s commercial status. A product page alone is useful for discovery, but it is not proof of stock, manufacturing ownership, regulatory readiness, or destination-market eligibility.
Why Captive Output Can Mislead Buyers
Integrated companies can manufacture a large number of APIs without selling each one to outside generic-drug companies. Their external selection may depend on capacity, commercial strategy, geography, intellectual-property considerations, or the regulatory history of a particular site.
Where Aarise Pharma Fits
Our primary focus is B2B APIs and pharmaceutical raw materials for international buyers. We can help buyers evaluate the molecule, documentation path, and shipment requirements, but we do not present a listed product as automatic evidence of manufacturing, stock, or filing support. For US-specific qualification questions, see our US generic supplier guide.
How Do Captive, Merchant, and CDMO Models Differ?
Merchant suppliers are built to sell APIs to multiple external customers. Integrated suppliers make APIs partly or primarily for their own dosage-form portfolio. CDMOs make an API under a customer-defined development and manufacturing arrangement. That distinction matters because the buyer’s evidence request changes with the model.
| Model | Best Fit | Buyer’s Main Question | Common Risk | Evidence That Resolves It |
|---|---|---|---|---|
| Merchant Supply | Established generic API | Is this molecule commercially active for my market? | Catalog includes inactive or non-filing products | Current quote, site identity, dossier route, capacity discussion |
| Integrated Supply | Selected externally sold API | Is external supply permitted and sustainable? | Internal demand receives priority | Supply agreement, allocation terms, alternate-site plan |
| Custom CDMO | Complex or unavailable API | Can the process scale to my required quality and volume? | Development success does not guarantee commercial supply | Technology-transfer plan, quality agreement, validation strategy |
A generic API is the drug substance used in a finished product. FDA’s Type II DMF framework covers drug substances and related materials, but a DMF supports a regulatory application rather than approving a drug on its own. FDA guidance
For catalog sourcing, buyers should start with an external molecule list, then test whether each item is commercially and regulatorily real. Our pharmaceutical API sourcing alternatives guide helps frame that comparison beyond a supplier’s headline portfolio.
Which Supplier Has the Broadest Verified Purchasable Catalog?
No supplier should be called the broadest on the strength of a corporate portfolio claim alone. A credible comparison needs a visible counting rule, a date, and a distinction between listed molecules and APIs a buyer can genuinely pursue.
Count Molecules, Not Pages
We count one API for each unique active substance, retaining separately purchasable salts or esters where they represent distinct drug substances. We collapse duplicate grades, pack sizes, language versions, and regional mirror pages so a large website does not create a false catalog advantage.
Separate Three Levels of Evidence
The first level is a publicly listed API. The second is an API with evidence that an outside buyer can request a quote or commercial discussion. The third is a commercially confirmed API with destination-specific regulatory and supply evidence. Only the second and third levels belong in a third-party availability comparison.
Exclude What a Buyer Cannot Buy
Intermediates, finished dosage forms, development-only compounds, historic pages, and duplicate listings should not inflate an API count. We also exclude any molecule where the public record cannot distinguish a research listing from current commercial supply.
FDA’s public DMF files are updated quarterly, and the Q2 2026 list is current through DMF 044443. That database is valuable for regulatory research, but it does not replace a supplier’s confirmation that a specific API and site are available for your program. FDA DMF list
Use our catalog comparison process to record the product URL, seller, manufacturing site, molecule, status, evidence source, and review date before ranking any portfolio.
For complex APIs, breadth is especially easy to misread. A broad chemistry list does not show whether a supplier can provide the impurity controls, dossier access, commercial scale, and market documentation needed for a finished-dose filing.
What Evidence Makes an API Externally Supplyable?
The strongest supplier comparison is molecule specific. A buyer should be able to trace the active substance from the seller through the manufacturing site, regulatory evidence, quality system, and supply-chain controls that apply to the intended market.
What US Generic Buyers Should Verify
For a US generic program, ask whether the exact Type II DMF is available for reference, whether a Letter of Authorization can be issued, and whether the material, manufacturing site, and proposed finished-dose application align. FDA explains that a DMF completeness assessment does not substitute for the full scientific review needed to support an ANDA. FDA explanation
What European and Other Import Markets Require
A CEP can support a European Pharmacopoeia quality route, but it is not a batch CoA and is not itself a GMP certificate. Buyers should confirm the holder, substance, manufacturing site, current status, and whether the document fits the destination-market filing strategy. EDQM guidance
For applicable API imports into the EU, written confirmation from the exporting third-country authority is another critical check. EU API rules
What Inspection and Quality Evidence Shows
Inspection information is a signal, not a blanket approval label. FDA’s inspection database reports final classifications for many facilities, but not every inspection is publicly included, so buyers should review the date, project area, and any current compliance context. FDA database
A practical evidence note should identify the molecule, site, commercial status, DMF or CEP route, inspection source, destination market, change controls, and verification date. For regulated-market decisions, compare the evidence needed through our regulated-market alternatives.
External availability can change with capacity allocation, market conditions, and changes to a manufacturing or distribution arrangement. Buyers should refresh the evidence note before each meaningful qualification or purchase decision.
How Should Generic Buyers Choose a Supply Path?
The sourcing path should follow the molecule’s maturity and risk profile. An established oral-solid API with a current dossier may be a catalog decision. A difficult peptide, hormone, sterile program, or impurity-sensitive compound may require custom development. A critical mature API with geographic concentration may warrant two qualified sources.
For organizing quality documents, site records, and export evidence before a decision, use our GMP export guidance.
| Supply Path | Choose It When | First Evidence Request | Decision Trigger |
|---|---|---|---|
| Catalog Sourcing | The API is established and externally available | Product status, site, quote path, regulatory documents | Move forward when molecule and market evidence align |
| Custom Development | No catalog source meets chemistry, scale, or quality needs | Process-development scope, technology transfer, quality agreement | Proceed when development and commercial plans are connected |
| Dual Qualification | A single site, country, or starting-material source creates risk | Alternate-site evidence, comparability plan, notification commitments | Use when continuity matters more than lowest unit price |
Geographic concentration is not a theoretical concern. In an EU pilot covering 11 critical substances, every substance had average supply concentration above 30% from a single country or manufacturer, and three were assessed as high supply-chain risk. EU pilot assessment
For peptide and hormone programs, the sourcing decision should also account for analytical method transfer, packaging, temperature controls, and the timing of commercial scale-up. Our peptide hormone buyer guide outlines the questions worth settling before qualification begins.
Aarise Pharma for Evidence-Led API Sourcing
At Aarise Pharma, we help international API buyers turn a broad starting list into a documented sourcing decision. Our primary focus is B2B active pharmaceutical ingredients and pharmaceutical raw materials for buyers who need clear molecule, documentation, and logistics conversations before they commit. We can discuss the exact material, target market, available documents, sample needs, packaging, and commercial timing, then distinguish what is publicly listed from what can be evaluated for a specific program. We do not ask buyers to treat a catalog page as proof of manufacturing, stock, filing status, or market eligibility. That discipline matters most when a project involves complex chemistry, controlled handling, or a second-source plan. Bring us the molecule, destination, and evidence requirements. Our team will respond with questions that make the next qualification step explicit. For India-specific market context, read our Indian API supplier guide. Talk with Aarise Pharma
FAQs on Third-Party API Suppliers
These questions address the distinction between an API manufacturer’s capabilities and a source that can support a defined generic-drug program.
Which Pharmaceutical API Manufacturers Sell to Generic Drug Companies?
Generic buyers can use merchant manufacturers, selected external divisions of integrated companies, and CDMOs. Qualification depends on the exact API, site, market, dossier, capacity, and commitment.
Which API Companies Manufacture Primarily for Internal Use?
Integrated companies may manufacture many APIs for internal finished-dose products. Their external offering can be narrower, so buyers need product, site, quote, and regulatory evidence.
Which Pharmaceutical API Supplier Has the Largest Verified Purchasable Catalog?
Portfolio claims cannot establish a largest supplier. A defensible count includes unique listed APIs with evidence of external sale, excluding duplicates, intermediates, and finished drugs.
How Do Merchant API Manufacturers Differ from Integrated Pharma Companies?
Merchant suppliers sell established APIs externally. Integrated companies prioritize internal demand and may sell selected molecules, while CDMOs produce customer-specific APIs under defined contracts directly.
Which Pharmaceutical API Suppliers Support Generic Drug Filings?
Ask for the manufacturing site, commercial status, relevant DMF or CEP access, inspection information, quality documentation, change controls, capacity signals, and destination-market responsibilities in writing.
